Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Go-It-Alone Approach Nets $1.95bn COVID Vaccine Order From US Government

Executive Summary

Supply agreement with the Health and Human Services Department and the Department of Defense reflects a profitable per dose price of $19.50 for an initial batch of 100 million doses of the vaccine candidate, pending FDA authorization or approval.

You may also be interested in...



Can China Convince World With Its Fast, Cheap COVID Vaccines?

As China gears up to the possible launch of its first vaccines against the coronavirus, supported by clearer regulations, many see the candidates as promising and cost-effective, although they may need more convincing data to be widely adopted. Relatively low projected per dose costs are generating interest in trials in multiple countries.

Stepping Up? Pharma’s Early COVID Pricing Decisions May Be Resolving Concerns

Cigna's Steve Miller suggests pharma is taking a responsible approach to pricing during the pandemic in a policy discussion convened by the Institute for Clinical and Economic Review on pricing models for COVID-19 drugs and vaccines.

The Challenges of Warp Speed: FDA, Administration Not Always On Same Page

Administration suggests Operation Warp Speed vaccines come with US FDA review speed advantage, but the agency backtracks on that assertion. FDA may need to get creative to ensure it has enough staff to quickly review all vaccines, expert says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel